JL, I wonder what your take on this commentary on the IMPROVE-IT trial where the authors downplay the pleiotropic effects of statins?
"The Real Value of the IMPROVE-IT The greatest value of the IMPROVE-IT study is its scientific message that corroborates the hypothesis that cholesterol is a cardiovascular risk factor. Statins reduce cholesterol levels and the cardiovascular risk, representing a criterion of reversibility and supporting this hypothesis. However, some critics argue that statins reduce cardiovascular risk by their pleiotropic effects rather than by reducing cholesterol levels. The IMPROVE-IT demonstrated that the additional reduction in cholesterol levels by a drug other than statin also reduce the cardiovascular risk, hence rejecting the null hypothesis of the relationship between cholesterol and cardiovascular risk.
And, sorry for the pun, but what the IMPROVE-IT actually improves is our scientific maturity.'"